You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Antibodies, Blocking

Showing 1 - 25 of 7,529
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Closely Grouped, Iterative Exposures to Suxamethonium During ECT

Recruiting
  • Depression
  • +2 more
  • Iterative exposure to suxamethonium during ECT sessions
  • Paris, France
    Saint-Antoine Hospital
Apr 4, 2022

Merkel Cell Carcinoma Trial in Germany, Netherlands (Nivolumab)

Active, not recruiting
  • Merkel Cell Carcinoma
  • Essen, NRW, Germany
  • +19 more
Jan 5, 2022

Malaria Trial run by the National Institute of Allergy and Infectious Diseases (NIAID) (Pvs230D1-EPA/Matrix-M)

Not yet recruiting
  • Malaria
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 28, 2023

Malaria Trial in Lambaréné (Vaccine AnAPN1)

Not yet recruiting
  • Malaria
  • Vaccine AnAPN1
  • Lambaréné, Moyen- Ogooué, Gabon
    Centre de Recherches Médicales de Lammbaréné
Jun 21, 2023

Glanzmann Thrombasthenia Trial in France (Antibodies screening)

Active, not recruiting
  • Glanzmann Thrombasthenia
  • Antibodies screening
  • Bordeaux, France
  • +8 more
Jul 5, 2022

Hypersensitivity, Immediate, Peri-operative Injury, Antibiotic Allergy Trial in Paris (IgG group, IgE group, IgG group + IgE

Not yet recruiting
  • Hypersensitivity, Immediate
  • +3 more
  • IgG group
  • +2 more
  • Paris, France
    Hôpital Bichat claude Bernard
Jun 10, 2022

IL-13 Blockade and Airway Autoimmunity in Asthma

Not yet recruiting
  • Airway Auto Immunity in Asthma
    • (no location specified)
    Sep 30, 2022

    Microenvironment of Lung Cancer and Exploration of Mechanism of

    Recruiting
    • Lung Cancer
    • Multiomics analysis
    • Yiwu, Zhejiang, China
      The Fourth Affiliated Hospital of Zhejiang University
    Dec 16, 2022

    Human Immunodeficiency Virus Trial in New York, Philadelphia (3BNC117-LS, 10-1074-LS, N803)

    Not yet recruiting
    • Human Immunodeficiency Virus
    • New York, New York
    • +2 more
    Jul 12, 2022

    SARS-CoV-2, Prevention Trial in Chongqing (MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray, Placebo Comparator: MY-586

    Recruiting
    • SARS-CoV-2
    • Prevention
    • MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray
    • Placebo Comparator: MY-586 SARS-CoV-2 Neutralization Antibody nasal excipient
    • Chongqing, Chongqing, China
      The Second Affiliated Hospital of Chongqing Medical University
    Aug 2, 2023

    EXploring Immune-related Adverse Events of Immune checkpoinT

    Active, not recruiting
    • Cancer
    • +2 more
    • Immune checkpoint inhibitor
    • Paris, France
    • +1 more
    Jul 5, 2023

    Blocking TNF to Potentiate ICI-dependent Immune Awakening in

    Recruiting
    • Melanoma
    • +2 more
      • Toulouse, France
        Institut Claudius Regaud
      May 25, 2023

      Kidney Transplantation, Graft Failure Trial in Toulouse (Tocilizumab)

      Recruiting
      • Kidney Transplantation
      • Graft Failure
      • Toulouse, France
        CHU Toulouse
      Mar 15, 2022

      Cancer, Tumors, Tumor Trial in Worldwide (BMS-986226, Nivolumab, Ipilimumab)

      Completed
      • Cancer
      • +3 more
      • Boston, Massachusetts
      • +12 more
      Mar 11, 2022

      Pancreatic Cancer Trial in Herlev (drug, biological, radiation)

      Recruiting
      • Pancreatic Cancer
      • Herlev, Denmark
        Herlev and Gentofte Hospital
      Mar 15, 2022

      Pancreatic Carcinoma, Tumors That Express CA 19-9 Trial in Scottsdale, New York (MVT-1075, MVT-5873)

      Suspended
      • Pancreatic Carcinoma
      • Tumors That Express CA 19-9
      • Scottsdale, Arizona
      • +1 more
      Aug 23, 2022

      Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V Trial in Beijing (KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

      Recruiting
      • Solid Tumor, Adult
      • +4 more
      • KRAS-EphA-2-CAR-DC
      • +3 more
      • Beijing, Beijing, China
        Biotherapeutic Department of Chinsese PLA Gereral Hospital
      Nov 29, 2022

      Solid Tumor, Adult, Lymphoma, EphA2 Overexpression Trial in Beijing (TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

      Recruiting
      • Solid Tumor, Adult
      • +6 more
      • TP53-EphA-2-CAR-DC
      • +3 more
      • Beijing, Beijing, China
        Biotherapeutic Department of Chinsese PLA Gereral Hospital
      Nov 29, 2022

      Community Dynamics of Malaria Transmission in Humans and

      Active, not recruiting
      • Malaria
        • Bethesda, Maryland
          Immunology and Pathogenesis Laboratories
        Dec 22, 2022

        Malaria,Falciparum Trial in Bamako (Pfs230D1-EPA/Matrix-M Vaccine, Verorab Rabies Vaccine)

        Active, not recruiting
        • Malaria,Falciparum
        • Pfs230D1-EPA/Matrix-M Vaccine
        • Verorab Rabies Vaccine
        • Bamako, Mali
          Malaria Research Training Center
        Sep 7, 2022

        Nephrotic Syndrome Trial in Genova (Rituximab Biosimilar ABP 798, Daratumumab)

        Not yet recruiting
        • Nephrotic Syndrome
        • Genova, Italy
          IRCCS G. Gaslini
        Jan 19, 2023

        Vaccine Adverse Reaction, Seroconversion Trial in Zagazig (SARS-Cov-2 neutralizing antibody titer)

        Completed
        • Vaccine Adverse Reaction
        • Seroconversion
        • SARS-Cov-2 neutralizing antibody titer
        • Zagazig, Sharkia, Egypt
          Zagazig University Faculty of Medicine
        Feb 7, 2022

        Membranous Nephropathy Trial in Nice (Peginterferon Alfa-2A 180 MCG/ML Injectable Solution)

        Not yet recruiting
        • Membranous Nephropathy
        • Peginterferon Alfa-2A 180 MCG/ML Injectable Solution
        • Nice, France
          CHU de NICE
        Jul 4, 2023

        Hiv Trial in Denmark, United Kingdom (Romidepsin, 3BNC117, Antiretrovirals)

        Active, not recruiting
        • Hiv
        • Aalborg, Denmark
        • +6 more
        Sep 3, 2021

        HIV-1-infection Trial in London (ConM SOSIP, EDC ConM SOSIP, ConS UFO)

        Active, not recruiting
        • HIV-1-infection
        • ConM SOSIP
        • +4 more
        • London, United Kingdom
          NIHR Imperial Clinical Resarch Facility
        Jul 25, 2022